Oncology

Deficient copies of gene leaves some patients more susceptible for melanoma.

An antibody derived from the human immune system may kill cancer cells with less harm to patient.

Top news of the day from across the health care landscape.

Novel agents using dill and parsley extracts show promise fighting cancer.

Targeting cancer-driving proteins may further efforts in personalized cancer medication research.

Chemotherapy has the potential to make cancer cells more susceptible to immunotherapy.

Design of formulations based on flavopiridol shows promise inhibiting brain cancer cell growth.

Top news of the day from across the health care landscape.

Researchers explore which patients with non-small cell lung cancer are more likely to respond to the immunotherapy atezolizumab.

Higher doses of radiation found as effective as lower dose radiation for breast cancer treatment.

Patients treated with stereotactic body radiation therapy seen to have an increased risk of non-cancer death.

Hexosamine biosynthetic pathway could lead to potential treatments for certain prostate cancers.

Study finds a large proportion of breast cancer patients are receiving enough follow-up heart scans.

Recent advances and updates in oncology and cancer drug development.

Researchers assess the monetary value for improved health status.

Diet and physical activity found to decrease the risk of developing multiple cancer types.

Top news of the day from across the health care landscape.

Biosimilars show promise for treatment of treat autoimmune diseases and hematological cancers.

RANK-inhibitor denosumab was able to stop cell growth and reduce cancer development in breast cancer samples with mutated-BRCA1.

Docetaxel-induced peripheral neuropathy found in castrate-resistant metastatic prostate cancer.

Researchers explore the capability of natural killer cells.

Study finds high out-of-pocket costs remain a barrier for initiation of oral cancer drugs.

Insurers have taken interest in outcomes-based contracts for specialty drugs and non-specialty drugs.

Nivolumab (Opdivo) is a PD-1 immune checkpoint inhibitor that prevents an anti-tumor immune response.

Inotuzumab ozogamicin is a novel antibody-drug conjugate comprised of a monoclonal antibody that targets the surface cell antigen CD22.

Isoform stabilizing drug may be effective targeting colitis and colon cancer.

A combination approach that targets stromal and pancreatic cancer cells showed decreased cancer cell proliferation and invasion.

Women receiving radiation and chemotherapy may experience damage to their ovaries.